statistiche ricercatore

MORE', Sonia

Distribuzione geografica

Continente	#
NA - Nord America	1.757
AS - Asia	1.093
EU - Europa	795
SA - Sud America	331
Continente sconosciuto - Info sul continente non disponibili	134
AF - Africa	77
OC - Oceania	2
Totale	4.189

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	1.684
VN - Vietnam	303
IT - Italia	264
SG - Singapore	262
BR - Brasile	261
CN - Cina	193
RU - Federazione Russa	169
HK - Hong Kong	156
DE - Germania	79
FR - Francia	71
FI - Finlandia	51
IN - India	39
CI - Costa d'Avorio	35
BD - Bangladesh	34
AR - Argentina	33
GB - Regno Unito	33
CA - Canada	29
MX - Messico	29
NL - Olanda	27
IE - Irlanda	23
AT - Austria	18
JP - Giappone	16
MA - Marocco	12
IQ - Iraq	11
ZA - Sudafrica	11
ID - Indonesia	10
SE - Svezia	10
EC - Ecuador	9
SA - Arabia Saudita	9
TR - Turchia	9
CO - Colombia	8
PL - Polonia	8
UA - Ucraina	8
VE - Venezuela	8
AE - Emirati Arabi Uniti	7
UZ - Uzbekistan	7
ES - Italia	6
PY - Paraguay	6
CR - Costa Rica	5
PK - Pakistan	5
HU - Ungheria	4
KE - Kenya	4
KR - Corea	4
MY - Malesia	4
PE - Perù	4
SN - Senegal	4
TN - Tunisia	4
BE - Belgio	3
DK - Danimarca	3
JO - Giordania	3
TH - Thailandia	3
TW - Taiwan	3
AU - Australia	2
BH - Bahrain	2
CH - Svizzera	2
DZ - Algeria	2
EG - Egitto	2
HN - Honduras	2
HR - Croazia	2
IS - Islanda	2
LT - Lituania	2
NP - Nepal	2
PH - Filippine	2
RO - Romania	2
SV - El Salvador	2
TT - Trinidad e Tobago	2
AL - Albania	1
AZ - Azerbaigian	1
BA - Bosnia-Erzegovina	1
BN - Brunei Darussalam	1
BO - Bolivia	1
BW - Botswana	1
DO - Repubblica Dominicana	1
GA - Gabon	1
GE - Georgia	1
GI - Gibilterra	1
GP - Guadalupe	1
GR - Grecia	1
GT - Guatemala	1
IL - Israele	1
KH - Cambogia	1
KZ - Kazakistan	1
LK - Sri Lanka	1
LU - Lussemburgo	1
MT - Malta	1
MU - Mauritius	1
OM - Oman	1
PA - Panama	1
PS - Palestinian Territory	1
PT - Portogallo	1
RS - Serbia	1
UY - Uruguay	1
Totale	4.055

Salva come PNG Salva come JPEG

Città	#
Ashburn	397
Dallas	374
Singapore	156
Hong Kong	153
San Jose	143
Council Bluffs	132
Ho Chi Minh City	110
Hanoi	61
Boardman	50
Los Angeles	43
Beijing	40
Munich	36
Abidjan	35
Helsinki	35
Lauterbourg	35
The Dalles	35
New York	28
São Paulo	28
Moscow	27
Dublin	23
Hefei	23
Chandler	22
Rome	22
Milan	21
Frankfurt am Main	18
Santa Clara	18
Chicago	17
Da Nang	16
Denver	16
Nuremberg	16
Buffalo	15
Turku	15
Mexico City	13
Orem	12
Montreal	11
Amsterdam	10
Ancona	10
Brooklyn	10
Chennai	10
Guangzhou	10
Haiphong	10
Tokyo	10
Biên Hòa	9
Phoenix	9
Turin	8
Warsaw	8
Bari	7
Bologna	7
Hải Dương	7
Johannesburg	7
Rio de Janeiro	7
Xi'an	7
Can Tho	6
Houston	6
Lawrence	6
Manchester	6
Princeton	6
Shenzhen	6
Tashkent	6
Atlanta	5
Baghdad	5
Boston	5
Curitiba	5
Fairfield	5
Falconara Marittima	5
Jiujiang	5
London	5
North Charleston	5
Poplar	5
Porto Alegre	5
Redmond	5
Salt Lake City	5
San Francisco	5
Seattle	5
Thái Nguyên	5
Washington	5
Belo Horizonte	4
Bowling Green	4
Buenos Aires	4
Camden	4
Caracas	4
Dakar	4
Huế	4
Miami	4
Mumbai	4
New Delhi	4
Osimo	4
Pescara	4
Ribeirão Preto	4
Santo André	4
Toronto	4
Tunis	4
Vienna	4
Yiwu	4
Bogotá	3
Brasília	3
Brussels	3
Columbus	3
Corridonia	3
Florence	3
Totale	2.559

Salva come PNG Salva come JPEG

Nome	#
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial	220
Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations	155
Real‐world assessment of treatment patterns and outcomes in patients with relapsed‐refractory multiple myeloma in an Italian haematological tertiary care centre	138
POOR RESPONSE TO FIRST BNT162B2 SARS-COV-2 VACCINE DOSE IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT	137
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data	132
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study	131
NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES	129
Current Main Topics in Multiple Myeloma	127
Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review	125
Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study	117
Breast Cancer With Release of Tumor Cells in Peripheral Blood Mimicking Acute Myeloid Leukemia	115
Frequency and Risk Factors for Venous Thromboembolism Among Patients with Multiple Myeloma or Aggressive Lymphoma: A 6-Year Single Center Retrospective Analysis	111
Developments in consolidation and maintenance strategies in post-remission multiple myeloma	111
Editorial: Reviews in hematologic malignancies	110
Hepatic, gastric and bone marrow AL amyloidosis that began with Budd-Chiari syndrome: a case report	109
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma	108
AL amyloidosis: an overview on diagnosis, staging system, and treatment	107
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety	107
Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment	106
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma	103
Long-Term Survival with Multiple Myeloma: An Italian Experience	103
Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights	102
A rare case of solitary plasmacytoma mimicking submucosal lesion of ascending colon: a case report and literature review	102
Clinicians’ Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy	101
Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy	101
Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences	99
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients	98
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study	97
Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group	94
The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management	85
Monoclonal antibodies: Leading actors in the relapsed/refractory multiple myeloma treatment	84
Plasma cell leukemia: first diagnostic approach in the laboratory\|Leucemia plasmacellulare: primo inquadramento diagnostico in laboratorio	83
Infection events in patients with newly diagnosed multiple myeloma with anti-CD38 monoclonal antibody-based first line regimens: A multicentric Italian experience	74
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments	74
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study	73
Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma Patients	70
Sequential Bispecific Antibodies in Functional and Clinical High Risk Multiple Myeloma, Manifesting with Extramedullary Disease at Relapse: A Case Report	69
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy	58
Novel Experimental Drugs for Treatment of Multiple Myeloma	58
The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?	19
Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application	14
Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy	14
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone	10
Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape	9
Totale	4.189

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	15.530
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	15.530

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	32	0	0	0	0	0	0	10	0	6	2	7	7
2022/2023	72	8	7	8	3	5	3	0	3	16	0	13	6
2023/2024	190	22	3	7	5	22	6	3	6	8	8	26	74
2024/2025	783	65	36	20	11	16	77	86	29	162	87	89	105
2025/2026	2.920	215	230	461	300	267	213	459	203	178	231	79	84
2026/2027	192	118	74	0	0	0	0	0	0	0	0	0	0
Totale													4.189